Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Our preliminary experience with dual-chamber DDD pacemakers is reported. Technological innovations of the device, atrio-ventricular electrode stability and sequential stimulation have contributed to improve the conditions of patients previously submitted to VVI pacemaker implantation. Primary indications for DDD pacemaker implantation in our series included 7 patients with complete atrio-ventricular (A-V) block, 3 with Mobitz type II second-degree A-V block and 2 with sick sinus syndrome. In six of the 12 patients (50%) additional indications included: ventricular tachycardia in 4 patients, atrial fibrillation in one and pacemaker syndrome in one. Other cardiac conditions were diagnosed: dilated cardiomyopathy in 3 patients, ischemic heart disease in 2 patients, valvular heart disease in 2 patients, congenital heart disease in 1 patient and hypertrophic cardiomyopathy in one patient. The implanted pacemakers were: 5 Genesis, 4 Ultra CPI and 3 Versatrax. J-shaped atrial electrodes were used in 8 patients and in 4 instances a screw-in electrode was employed. Improvement of hemodynamic function was achieved by frequent follow up and reprogramming of DDD pacemaker in every patient. While 4 patients died with progressive deterioration of cardiac function, eight patients survived with adequate sequential stimulation. We conclude that DDD pacemakers are reliable and afford symptomatic relief in a broad spectrum of patients.
 ...
PMID:[DDD dual chamber pacemakers. Initial experience]. 134 19

In published series of nonthoractomy ICDs, there has invariably been a need for combining transvenous lead(s) with a subcutaneous patch to obtain adequate DFTs. Since the newer generation transvenous lead ICD systems became available for clinical investigation, we have tested and implanted 38 such systems in patients with drug-refractory malignant ventricular arrhythmias who were first seen with aborted sudden death (n = 10), syncope (n = 3), or sustained ventricular tachycardia (n = 25). These patients (mean age 60 +/- 15 years) had coronary artery disease (n = 25), congenital heart disease (n = 1), or cardiomyopathy (n = 12) as the underlying heart disease and a mean left ventricular ejection fraction of 34% +/- 16%. Seventeen (45%) patients had previous cardiac surgery (coronary bypass and/or valve replacement). The transvenous lead system included the Endotak C (single) lead of CPI (n = 27) or the EnGuard double-lead system of Telectronics (n = 11). The integrated pace/sense/defibrillation lead(s) were usually introduced via the left cephalic vein; after endocardiac positioning and testing, the leads were tunneled to the abdominal pocket in which the ICD device was implanted. DFTs were adequate for all patients (100%) and averaged 13.5 +/- 5.4 J (range 2.4 to 25 J). A subcutaneous patch or array was needed in only three patients. Because of protocol requirements, a subcutaneous patch or electrode array was intraoperatively tested in another three patients but was finally not implanted because better DFTs were achieved with the transvenous lead-alone configuration. The leads were combined with second-generation devices in 12 patients and third-generation ICDs in 26 (68%) patients.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Fully transvenous cardioverter defibrillators: rare need for subcutaneous patch with two newer-generation systems. 794 52

Thirty-seven patients with ventricular tachyarrhythmias refractory to antiarrhythmic drug treatment, guided by electrophysiological testing, were submitted to implantation of a cardioverter-defibrillator by the transvenous technique. Mean age was 55 +/- 14 years and the underlying heart disease was coronary heart disease in 24 patients, cardiomyopathy or other etiologies in 11 patients. In 2 patients ventricular arrhythmias were idiopathic. Left ventricular ejection fraction was < or equal to 40% in 65% of the patients. The following devices were implanted: CPI Ventak P in 2 patients, Ventak P2 in 9 patients, Ventak PRx in 9 patients, Ventak PRxII in 2 patients, Telectronics Guardian ATP III 4215 in 9 patients, Siemens Siecure in 5 patients, Medtronic Jewel PCD in 1 patient. At implantation defibrillation threshold was lower with biphasic shocks than with monophasic shocks (17.0 +/- 3.2 vs 20.9 +/- 3.8 J, p < 0.003) and the need for subcutaneous patches was lower when biphasic shocks were employed. Operative and perioperative mortality were 0% and no significant complications were observed. During the follow-up (16 +/- 11 months) 35% of the patients had appropriate shocks and 93% of the patients with antitachycardia pacing availability (n = 15) had effective antitachycardia pacing interventions. The following complications were observed: lead failure in 4 patients (3 insulation breaks and 1 elongation for stretching), late lead dislodgement in 2 patients, lead recall in 1 patient, all of which required reintervention. Inappropriate shocks occurred in 30% of the patients and were related to lead failure, supraventricular arrhythmias or alternating current interference. During the follow-up one patient died of sudden death and one was submitted to heart transplantation. In conclusion, implantation of a cardioverter-defibrillator by the transvenous technique is a procedure relatively free from complications. During the follow-up lead failure appears to be one of the most relevant complications. Antitachycardia pacing allows effective termination of ventricular tachycardias without cardioversion, with a better compliance.
 ...
PMID:[Transvenous cardioverter-defibrillators: clinical experience at implantation and follow-up]. 864 Aug 50